A Toolbox for the Generation of Chemical Probes for Baculovirus IAP Repeat Containing Proteins

被引:10
作者
Schwalm, Martin P. [1 ,2 ]
Berger, Lena M. [1 ,2 ]
Meuter, Maximilian N. [1 ]
Vasta, James D. [3 ]
Corona, Cesear R. [3 ]
Roehm, Sandra [1 ,2 ]
Berger, Benedict-Tilman [1 ,2 ]
Farges, Frederic [1 ]
Beinert, Sebastian M. [1 ]
Preuss, Franziska [1 ,2 ]
Morasch, Viktoria [1 ,2 ]
Rogov, Vladimir V. [1 ,2 ]
Mathea, Sebastian [1 ,2 ]
Saxena, Krishna [1 ,2 ]
Robers, Matthew B. [3 ]
Mueller, Susanne [1 ,2 ]
Knapp, Stefan [1 ,2 ,4 ]
机构
[1] Goethe Univ, Inst Pharmaceut Chem, Dept Biochem Chem & Pharm, Frankfurt, Germany
[2] Goethe Univ, Buchmann Inst Mol Life Sci, Struct Genom Consortium, Frankfurt, Germany
[3] Promega Corp, Madison, WI USA
[4] German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Heidelberg, Germany
来源
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2022年 / 10卷
关键词
IAP; E3; Ligase; PROTAC; Ubiquitin; NanoBRET; KAPPA-B ACTIVATION; CLINICAL CANDIDATE; APOPTOSIS PROTEINS; ANTAGONISTS INDUCE; INHIBITOR; CANCER; POTENT; DOMAIN; XIAP; DISCOVERY;
D O I
10.3389/fcell.2022.886537
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
E3 ligases constitute a large and diverse family of proteins that play a central role in regulating protein homeostasis by recruiting substrate proteins via recruitment domains to the proteasomal degradation machinery. Small molecules can either inhibit, modulate or hijack E3 function. The latter class of small molecules led to the development of selective protein degraders, such as PROTACs (PROteolysis TArgeting Chimeras), that recruit protein targets to the ubiquitin system leading to a new class of pharmacologically active drugs and to new therapeutic options. Recent efforts have focused on the E3 family of Baculovirus IAP Repeat (BIR) domains that comprise a structurally conserved but diverse 70 amino acid long protein interaction domain. In the human proteome, 16 BIR domains have been identified, among them promising drug targets such as the Inhibitors of Apoptosis (IAP) family, that typically contain three BIR domains (BIR1, BIR2, and BIR3). To date, this target area lacks assay tools that would allow comprehensive evaluation of inhibitor selectivity. As a consequence, the selectivity of current BIR domain targeting inhibitors is unknown. To this end, we developed assays that allow determination of inhibitor selectivity in vitro as well as in cellulo. Using this toolbox, we have characterized available BIR domain inhibitors. The characterized chemical starting points and selectivity data will be the basis for the generation of new chemical probes for IAP proteins with well-characterized mode of action and provide the basis for future drug discovery efforts and the development of PROTACs and molecular glues.
引用
收藏
页数:13
相关论文
共 40 条
  • [1] Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism
    Allensworth, Jennifer L.
    Sauer, Scott J.
    Lyerly, H. Kim
    Morse, Michael A.
    Devi, Gayathri R.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 359 - 371
  • [2] Validating survivin as a cancer therapeutic target
    Altieri, DC
    [J]. NATURE REVIEWS CANCER, 2003, 3 (01) : 46 - 54
  • [3] Berthelet Jean, 2013, Cells, V2, P163, DOI 10.3390/cells2010163
  • [4] A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment
    Cai, Qian
    Sun, Haiying
    Peng, Yuefeng
    Lu, Jianfeng
    Nikolovska-Coleska, Zaneta
    McEachern, Donna
    Liu, Liu
    Qiu, Su
    Yang, Chao-Yie
    Miller, Rebecca
    Yi, Han
    Zhang, Tao
    Sun, Duxin
    Kang, Sanmao
    Guo, Ming
    Leopold, Lance
    Yang, Dajun
    Wang, Shaomeng
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (08) : 2714 - 2726
  • [5] The evolution of BIR domain and its containing proteins
    Cao, Lihuan
    Wang, Zhenghan
    Yang, Xianmei
    Xie, Li
    Yu, Long
    [J]. FEBS LETTERS, 2008, 582 (27): : 3817 - 3822
  • [6] CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
  • [7] RING Domain E3 Ubiquitin Ligases
    Deshaies, Raymond J.
    Joazeiro, Claudio A. P.
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2009, 78 : 399 - 434
  • [8] IAPs - More than just inhibitors of apoptosis proteins
    Dubrez-Daloz, Laurence
    Dupoux, Alban
    Cartier, Jessy
    [J]. CELL CYCLE, 2008, 7 (08) : 1036 - 1046
  • [9] Antagonists Induce a Conformational Change in cIAP1 That Promotes Autoubiquitination
    Dueber, Erin C.
    Schoeffler, Allyn J.
    Lingel, Andreas
    Elliott, J. Michael
    Fedorova, Anna V.
    Giannetti, Anthony M.
    Zobel, Kerry
    Maurer, Brigitte
    Varfolomeev, Eugene
    Wu, Ping
    Wallweber, Heidi J. A.
    Hymowitz, Sarah G.
    Deshayes, Kurt
    Vucic, Domagoj
    Fairbrother, Wayne J.
    [J]. SCIENCE, 2011, 334 (6054) : 376 - 380
  • [10] Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
    Eckelman, Brendan P.
    Salvesen, Guy S.
    Scott, Fiona L.
    [J]. EMBO REPORTS, 2006, 7 (10) : 988 - 994